Vutisiri Veerasarn1, Wiroon Boonnuch, Chumpot Kakanaporn. 1. Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. Vutisiri@hotmail.com
Abstract
OBJECTIVE: To evaluate efficacy and safety of WF10 (TCDO iv solution) therapy in patients with late hemorrhagic radiation cystitis and proctitis in a long-term follow up. MATERIAL AND METHODS: From February 1999 to July 2001, 30 symptomatic patients with endoscopically confirmed grade 2 and 3 late hemorrhagic cystitis (n = 16) and proctitis (n = 14) were treated with WF10. The dose was 0.5 ml/kg BW, diluted in 250 ml 5%D/W, administered by intravenous infusion over 2 h, 5 consecutive days, every 3 weeks for 2-4 cycles, combined with standard therapy. The patients were clinically followed up every 3 weeks for 3 months, then every 3 months for 1 year and then every 3-6 months. The study endpoints were immediate response with improvement to Grade 0-1 within 3 months and the incidence of recurrence to Grade > or =2 during the follow up time. RESULTS: After completion of the WF10 therapy, 14 cystitis patients (88%) had improved to grade 0-1 hematuria, and 14 proctitis patients (100%) had improved in bleeding per rectum to grade 0-1 within 3 months. The median follow up time was 51 months. During the follow up period, among the responders, 4 cystitis patients (28%) had recurrent hematuria of grade 2 and two proctitis patients (14%) had recurrent bleeding per rectum of grade 2 and 3. No treatment toxicity was observed. CONCLUSION: The WF10 therapy combined with conventional treatment is simple and safe with long-term efficacy in the treatment of late hemorrhagic radiation cystitis and proctitis.
OBJECTIVE: To evaluate efficacy and safety of WF10 (TCDO iv solution) therapy in patients with late hemorrhagic radiation cystitis and proctitis in a long-term follow up. MATERIAL AND METHODS: From February 1999 to July 2001, 30 symptomatic patients with endoscopically confirmed grade 2 and 3 late hemorrhagic cystitis (n = 16) and proctitis (n = 14) were treated with WF10. The dose was 0.5 ml/kg BW, diluted in 250 ml 5%D/W, administered by intravenous infusion over 2 h, 5 consecutive days, every 3 weeks for 2-4 cycles, combined with standard therapy. The patients were clinically followed up every 3 weeks for 3 months, then every 3 months for 1 year and then every 3-6 months. The study endpoints were immediate response with improvement to Grade 0-1 within 3 months and the incidence of recurrence to Grade > or =2 during the follow up time. RESULTS: After completion of the WF10 therapy, 14 cystitispatients (88%) had improved to grade 0-1 hematuria, and 14 proctitispatients (100%) had improved in bleeding per rectum to grade 0-1 within 3 months. The median follow up time was 51 months. During the follow up period, among the responders, 4 cystitispatients (28%) had recurrent hematuria of grade 2 and two proctitispatients (14%) had recurrent bleeding per rectum of grade 2 and 3. No treatment toxicity was observed. CONCLUSION: The WF10 therapy combined with conventional treatment is simple and safe with long-term efficacy in the treatment of late hemorrhagic radiation cystitis and proctitis.
Authors: Bharathi Raja Rajaganapathy; Joseph J Janicki; Peter Levanovich; Pradeep Tyagi; Jason Hafron; Michael B Chancellor; Sarah Krueger; Brian Marples Journal: J Urol Date: 2015-04-01 Impact factor: 7.450
Authors: Ilia A Dereven'kov; Nikita I Shpagilev; László Valkai; Denis S Salnikov; Attila K Horváth; Sergei V Makarov Journal: J Biol Inorg Chem Date: 2016-11-19 Impact factor: 3.358
Authors: C Martini; A Hammerer-Lercher; M Zuck; A Jekle; D Debabov; M Anderson; M Nagl Journal: Antimicrob Agents Chemother Date: 2012-01-17 Impact factor: 5.191
Authors: J Nirmal; A S Wolf-Johnston; M B Chancellor; P Tyagi; M Anthony; J Kaufman; L A Birder Journal: Int Urol Nephrol Date: 2014-05-30 Impact factor: 2.370
Authors: Fleur T van de Wetering; Leen Verleye; H Jervoise N Andreyev; Jane Maher; Joan Vlayen; Bradley R Pieters; Geertjan van Tienhoven; Rob J P M Scholten Journal: Cochrane Database Syst Rev Date: 2016-04-25